We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Study Pinpoints Biomarker Signature of MS

By LabMedica International staff writers
Posted on 07 Nov 2017
Researchers have identified unique dysregulated microRNAs (miRNAs) from exosomes in the blood of Multiple Sclerosis (MS) patients. More...
The findings could lead to development of a simple diagnostic blood test for this debilitating chronic neurologic disease.

Currently, there is no definitive test for MS. Diagnosis and disease monitoring relies on several parameters, including clinical examination, MRI, cerebrospinal fluid assessment, and electrophysiology. These tests are costly and still have limited utility to discriminate between different stages of the disease.

The study was led by researchers at University of Sydney (Sydney, Australia) and Royal Prince Alfred Hospital (Australia), and was made possible through the generosity of patients at Brain & Mind Centre’s multidisciplinary Multiple Sclerosis Clinic.

The team previously showed that some miRNAs are selectively packaged into exosomes for release from the cell. Exosomes circulate in blood and can be purified in the millions from a single vial of blood. They are released by healthy and diseased cells, circulate throughout the body, and can deliver cargo of information to multiple cells.

In inflammatory diseases such as MS, there is a significant increase in circulating exosome concentrations. Given that exosomes can cross the blood-brain barrier, it is likely that some of the circulating exosomes in MS patients come from affected central nervous system cells or the associated inflammatory milieu. The researchers hypothesized that physiological changes associated with MS and its progression is reflected in differences in serum exosomal miRNAs, so they investigated their utility as biomarkers of MS.

“In studying the blood exosomes of healthy volunteers and patients with MS, the research team identified a molecular signature of MS that not only correctly diagnoses MS, but also discriminates between patients with different stages of disease,” said Michael Buckland, of RPA Hospital and associate professor at University of Sydney. Using next-generation sequencing (NGS) and integrative bioinformatics they found that serum exosome miRNA profiles not only distinguish MS from healthy controls, but also distinguish between 2 MS subtypes: relapsing-remitting MS (RRMS) and progressive MS. The team identified 9 unique miRNA molecules that differentiate between these two subtypes. They validated 8 of the 9 miRNAs in an independent group of progressive MS cases, providing reproducibility of the findings.

“This is the first demonstration that miRNAs associated with circulating exosomes in blood are informative biomarkers not only for the diagnosis of MS, but in predicting disease subtypes with a high degree of accuracy,” said Prof. Buckland.

“This blood test may allow people with MS to begin treatment earlier, and identify the most appropriate treatment for their condition,” said Dr Matthew Miles, CEO MS Research Australia, which funded the research via an incubator grant, “This, in turn may lead to fewer relapses and a slower loss of brain volume, resulting in slowing or potentially halting progression of the disease for the person living with MS. It will also help remove the uncertainty surrounding which subtype of the disease an individual has and therefore be a catalyst for better outcomes.”

The study, by Ebrahimkhani S et al, was published October 31, 2017, in the journal Nature Scientific Reports.

Related Links:
University of Sydney
Royal Prince Alfred Hospital

New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.